GlassScriptPhysician profile
James Clyde Barton
NPI 1477645992
$7,940.22
in general payments reported to CMS, 2019-2025
52 companies · $925 in 2025
The $925 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,377 · 2020: $549 · 2021: $1,349 · 2022: $1,388 · 2023: $1,190 · 2024: $1,161 · 2025: $925.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,276.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $810.65 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $693.23 | 2019-2025 | |
| Amgen INC. | $602.66 | 2019-2023 | Kyprolis, Lumakras, Xgeva |
| Janssen Biotech, INC. | $589.37 | 2019-2025 | Darzalex, Talvey, Imbruvica |
| Incyte Corporation | $516.27 | 2021-2025 | Monjuvi, Jakafi, Pemazyre |
| Csl Behring | $503.77 | 2019-2025 | Hizentra |
| Genentech USA, INC. | $490.86 | 2019-2025 | Tecentriq, Venclexta, Phesgo |
| Octapharma USA, INC. | $463.73 | 2020-2025 | Octagam Immune Globulin (Human), Panzyga |
| E.R. Squibb & Sons, L.L.C. | $398.51 | 2019-2025 | Opdivo |
| Abbvie INC. | $342.50 | 2019-2025 | Venclexta |
| Glaxosmithkline, LLC. | $274.91 | 2021-2025 | Ojjaara, Jemperli |
| Pharmaessentia USA Corporation | $199.57 | 2023-2025 | Besremi |
| Seagen INC. | $193.93 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $170.46 | 2019-2024 | Imfinzi, Lynparza, Tagrisso |
| Beigene USA, INC. | $111.35 | 2023-2024 | Brukinsa |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Barton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.